Literature DB >> 1813893

Psychopharmacologic considerations in the treatment of black American populations.

T L Strickland1, V Ranganath, K M Lin, R E Poland, R Mendoza, M W Smith.   

Abstract

Although striking ethnic differences in pharmacologic responses to various medications have been documented in the general medical literature, there is a paucity of such information in the psychopharmacologic literature. Recent work has provided a number of studies that illustrate interesting inter-ethnic pharmacogenetic, pharmacokinetic, and pharmacodynamic differences. In general, however, such studies have reported inconsistent findings relative to dose response relationships with various psychotropics. Results of our literature review, with a particular focus on black Americans, suggest that the lack of consistency in these investigations is largely attributable to various methodological and design problems. Prominent among these problems are: diagnostic misclassification, treatment of various ethnic groups in a homogeneous undifferentiated manner, lack of appropriate control for age and gender, and minimal consideration for chronicity of illness. As a result, though there exist some interesting data suggesting inter-ethnic genetic and kinetic differences, the extant literature on black Americans and other ethnic groups should be evaluated with some caution. The purpose of this article is to provide a systematic review of the existing psychopharmacologic literature on the black American population.

Mesh:

Substances:

Year:  1991        PMID: 1813893

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  9 in total

Review 1.  Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.

Authors:  Valentine J Burroughs; Randall W Maxey; Richard A Levy
Journal:  J Natl Med Assoc       Date:  2002-10       Impact factor: 1.798

Review 2.  Optimising the economic efficiency of drug studies.

Authors:  M E Kitler
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

3.  Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis.

Authors:  M E Mooney; V I Reus; J Gorecki; S M Hall; G L Humfleet; R F Muñoz; K Delucchi
Journal:  Clin Pharmacol Ther       Date:  2007-08-08       Impact factor: 6.875

4.  Black and white patients response to antidepressant treatment for major depression.

Authors:  R V Varner; P Ruiz; D R Small
Journal:  Psychiatr Q       Date:  1998

Review 5.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

6.  Ethnocultural allodynia.

Authors:  L Comas-Díaz; F M Jacobsen
Journal:  J Psychother Pract Res       Date:  2001

7.  Race, genetic ancestry and response to antidepressant treatment for major depression.

Authors:  Eleanor Murphy; Liping Hou; Brion S Maher; Girma Woldehawariat; Layla Kassem; Nirmala Akula; Gonzalo Laje; Francis J McMahon
Journal:  Neuropsychopharmacology       Date:  2013-07-05       Impact factor: 7.853

8.  Antidepressant prescribing patterns: a comparison of blacks and whites in a medicaid population.

Authors:  D A Sclar; L M Robison; T L Skaer; W M Dickson; C M Kozma; C E Reeder
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

9.  Are there racial differences in the experience of harmful or traumatic events within psychiatric settings?

Authors:  Karen J Cusack; Anouk L Grubaugh; Eunsil Yim; Rebecca G Knapp; Cynthia S Robins; B Christopher Frueh
Journal:  Psychiatr Q       Date:  2007-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.